Rhythm Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RYTM research report →
Range $120 – $160
Price Chart
About the company
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R).
- CEO
- David Meeker
- IPO
- 2017
- Employees
- 414
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on RYTM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.79B
- P/E
- -39.91
- Fwd P/E
- 67.34
- PEG
- -6.24
- P/S
- 28.58
- P/B
- 39.65
- EV/EBITDA
- -46.10
- Div Yield
- 0.00%
- Gross Margin
- 88.23%
- Op Margin
- -66.70%
- Net Margin
- -69.03%
- ROE
- -83.68%
- ROIC
- -63.91%
Latest fiscal year · YoY change
- Revenue
- $189.76M+45.8%
- Gross Profit
- $170.26M+45.8%
- Op Income
- $-192,016,000
- Net Income
- $-196,539,000+24.6%
- EPS
- $-3.11+28.3%
- OCF Growth
- -1.6%
- FCF Growth
- -2.4%
- 52W High
- $122.20
- 52W Low
- $74.50
- 50D MA
- $97.93
- 200D MA
- $97.40
- Beta
- 2.13
- RSI (14)
- 62
- Avg Volume
- 1.08M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Rhythm delivered a strong Q3 with IMCIVREE-driven revenue growth, rapid U.S. HO launch execution, and a strategic pivot to deepen its bivamelagon franchise ahead of multiple 2027 catalysts.· November 3, 2026
- Q3 net product sales were $92.1 million, up 29% sequentially from $71.3 million in Q2, driven mainly by the U.S. acquired HO launch.
- U.S. HO launch momentum stayed strong: more than 700 patient start forms since launch, more than 500 prescribers, and reimbursed patients on therapy up 20% in the quarter.
- Payer access improved meaningfully, with policies covering about 60% of Medicaid lives and 75% of commercial lives, and over 80% of approvals coming within 60 days.
- Rhythm amended its LG Chem deal to reduce bivamelagon royalty exposure to a 1% flat royalty if U.S. approval is achieved, in exchange for $350 million paid over four years.
- Management outlined a 2027 pipeline path, including a phase III HO study for bivamelagon now and a planned six-month phase III PWS study with HQ-CT as the primary endpoint.
Rhythm reported third-quarter 2026 global net product sales of IMCIVREE of $92.1 million, up 29% sequentially from $71.3 million in Q2. U.S. revenue was $67.5 million, or 73% of product revenue, and international revenue was $24.7 million. Cost of goods sold was 13.2% of product revenue. R&D expense was $52.5 million versus $46.0 million a year ago, SG&A was $66.8 million, and GAAP EPS was a net loss of $0.61 per basic and diluted share, including $0.01 per share from accrued dividends. Cash used in operations was approximately $3 million, and the company ended the quarter with about $321 million in cash equivalents and short-term investments. For 2026, Rhythm raised full-year non-GAAP operating expense guidance to approximately $360 million-$380 million, including non-GAAP R&D of $165 million-$175 million and non-GAAP SG&A of $195 million-$205 million. Management said the R&D midpoint was reduced by $15 million because some research and formulation work moved from late 2026 into early 2027.
David Meeker sounded upbeat and strategically confident, framing the quarter as confirmation that the acquired HO opportunity is real and that the company has multiple long-term growth pillars. He emphasized that Rhythm wants to keep expanding its MC4R franchise, including genetic indications, hypothalamic obesity, and Prader-Willi syndrome, and said future portfolio updates will come in 2027. He also highlighted the rationale for starting bivamelagon development now, saying the company wants to follow the science and build the best possible treatment approach, including combination strategies over time.
Hunter Smith focused on the financial strength of the quarter and the strategic financing package. He detailed the LG Chem amendment, including the move to a 1% flat royalty assumption upon U.S. approval, $350 million in installment payments over four years, and additional milestone obligations, while noting that the present value of those fixed payments will be recognized in Q4 R&D expense. He also described a five-year term loan facility of up to $750 million, with $250 million to be drawn initially, SOFR plus 4.6% interest, no scheduled principal amortization before maturity, and no equity component. On liquidity, he said Rhythm ended Q3 with about $321 million in cash equivalents and short-term investments and expects that to fund planned operations for at least 24 months, before the initial $70 million LG payment and before any loan proceeds are reflected in cash.
Analysts focused mainly on the pace and durability of the acquired HO launch, especially patient start form trends, reimbursement conversion, prescriber awareness, and whether access improvements would accelerate future growth. Management said the launch is still early, with a steady rather than spiky uptake pattern, and attributed conversion to a mix of diagnosed patients, newly suspected patients, and physicians still learning to recognize acquired HO. On access, Jennifer Lee said approval timing should stay roughly similar going forward, with continued improvement in covered lives as payer meetings progress. Questions also centered on Japan and Prader-Willi: management said Japan could become a major market because of its centralized healthcare system, national coverage, and the 1,000+ patients already identified, while for PWS they said the planned phase III will use a six-month hyperphagia endpoint, still collect BMI data, and likely follow the precedent set by prior rare-disease approvals.
The bull case from this call is that acquired HO is becoming a real commercial franchise, with strong early demand, broad prescriber adoption, and improving payer access all moving in the right direction. Management also pointed to multiple future growth engines: Japan launch momentum, Europe coming in 2027, and a more aligned bivamelagon economics structure that could support a broader MC4R portfolio.
The main risks are that acquired HO remains a very early launch, with management repeatedly stressing that diagnosis, education, and reimbursement conversion all take time and may continue to progress at a steady rather than accelerating pace. The company is also taking on significant future commitments through the LG Chem amendment and the new term loan, while the Prader-Willi program still faces clinical and regulatory uncertainty in a historically difficult indication.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 81.5%
- Shares Outstanding
- 69.33M
- Float Shares
- 56.52M
of shares held by institutions
315 13F filers
Buy/sell ratio 0.25. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 6.67M | 0 |
| Vanguard Group Inc | 6.21M | ▲ 1.21M |
| Blackrock, Inc. | 6.16M | ▼ 80.25K |
| Baker Bros. Advisors LP | 5.60M | 0 |
| Jpmorgan Chase & Co | 3.56M | ▲ 905.48K |
| Vanguard Portfolio Management LLC | 3.14M | ▲ 96.18K |
| Primecap Management Co | 3.06M | ▼ 104.54K |
| Vanguard Capital Management LLC | 3.01M | ▲ 38.15K |
| State Street Corp | 2.64M | ▲ 65.21K |
| Perceptive Advisors LLC | 2.59M | ▲ 212.50K |
| Price T Rowe Associates Inc | 2.57M | ▲ 911.29K |
| Westfield Capital Management Co LP | 2.48M | ▲ 272.10K |
Held by 377 ETFs
Biggest fund positions in RYTM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | JEAN CHRISTOPHE | other | 10,000 |
| Nov 17, 26 | JEAN CHRISTOPHE | sell | 5,000 |
| Nov 17, 26 | JEAN CHRISTOPHE | sell | 2,500 |
| Nov 17, 26 | JEAN CHRISTOPHE | sell | 2,500 |
| Nov 17, 26 | JEAN CHRISTOPHE | other | 10,000 |
| Sep 14, 26 | Meeker David P | other | 50,000 |
| Sep 14, 26 | Meeker David P | sell | 6,439 |
| Sep 14, 26 | Meeker David P | sell | 30,746 |
| Sep 14, 26 | Meeker David P | sell | 8,698 |
| Sep 14, 26 | Meeker David P | sell | 1,817 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RYTM coverage
Recent articles, reports, and earnings notes.
Want a deeper read on RYTM?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Has Consensus Target Price of $142.00
defenseworld.net · Nov 19
Rhythm Pharmaceuticals Shares See Volume; Traders Circulate M&A Rumors At $150/Share
benzinga.com · Nov 17
Rhythm Pharmaceuticals Says Rare Obesity Drug Delivers Sustained Two-Year BMI Reductions
benzinga.com · Nov 17
Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026
globenewswire.com · Nov 16
Rhythm Pharmaceuticals (NASDAQ:RYTM) & Senti Biosciences (NASDAQ:SNTI) Head to Head Survey
defenseworld.net · Nov 11
Rhythm Pharmaceuticals: Bull Case Intact, But The Market Is Pricing In A Lot
seekingalpha.com · Nov 10
AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
wsj.com · Nov 4
Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome
globenewswire.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
